<DOC>
	<DOCNO>NCT00932698</DOCNO>
	<brief_summary>This study determine safety profile , tolerability , maximum tolerate dose ( MTD ) disease response IXAZOMIB administer orally patient relapse and/or refractory multiple myeloma .</brief_summary>
	<brief_title>Study Oral IXAZOMIB Adult Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : Multiple myeloma diagnose accord standard criterion . Patients multiple myeloma relapse follow least 2 line therapy . Patients must measurable disease . ECOG performance status 0 2 . Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception abstain heterosexual intercourse . Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse . Voluntary write consent . Suitable venous access studyrequired blood sampling . Patients meet follow exclusion criterion enrol study : Peripheral neuropathy &gt; equal Grade 2 . Female patient lactate positive serum pregnancy test screening period . Major surgery within 14 day first dose study drug . Infection require systemic antibiotic therapy serious infection within 14 day first dose study treatment . Lifethreatening illness unrelated cancer . Diarrhea &gt; Grade 1 , base NCI CTCAE categorization . Systemic antineoplastic radiation therapy within 14 day cytotoxic agent within 21 day first dose study treatment . Treatment investigational product within 21 day first dose study treatment . Treatment investigational proteasome inhibitor . Systemic treatment prohibit medication . Ongoing therapy corticosteroid great 10mg prednisone equivalent per day . Inhaled topical steroid permit . Central nervous system involvement . Evidence current uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure , angina , myocardial infarction within past 6 month . QTc &gt; 470 millisecond 12lead ECG obtain screening period . Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive status , know suspect active hepatitis C infection . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Known gastrointestinal ( GI ) disease GI procedure could interfere oral absorption tolerance IXAZOMIB include difficulty swallowing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Relapsed multiple myeloma</keyword>
	<keyword>Refractory multiple myeloma</keyword>
	<keyword>IXAZOMIB Proteasome inhibitor</keyword>
</DOC>